At a glance
ClinicalIndex Comparison RecordPhase 2Active· 49 enrolled
Drug / intervention
RP-3500 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
RP-3500 (ATRi) + External Beam Radiotherapy (EBRT) for the Palliative Treatment of Metastatic Disease
In Brief
A Phase 2 clinical trial evaluating RP-3500 and External Beam Radiotherapy (EBRT) for Solid Tumor and Metastatic Cancer. Active but no longer recruiting, targeting 49 participants across 7 sites.
Detailed Summary
The purpose of this study is to test the safety of the study drug, RP-3500 when given in combination with palliative external beam radiotherapy (EBRT) to people who have metastatic solid tumor cancer with a mutation of the ATM gene. The study researchers will do tests to find the highest dose of RP3500 that causes few or mild side effects.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSolid Tumor, Metastatic Cancer
CountriesUnited States
CollaboratorsRepare Therapeutics
Timeline
Phase 2Active
2023202420252026
Enrollment StartSep 2022
First PostedOct 2022
TodayJul 2026
Primary CompletionSep 2026
First PostedOct 4, 2022
Enrollment StartSep 30, 2022
Primary CompletionSep 30, 2026
TodayJul 1, 2026
Enrollment to primary: 4 yearsPosted 3.7 years agoPrimary completion in 3 months
Interventions
RP-3500drug
RP-3500 on Days 1-5.
External Beam Radiotherapy (EBRT)radiation
Palliative radiation therapy (4Gy x 5 fractions) to a metastatic site on Days 1-5